On this page
Educational information, not medical advice. GLP-1 medications need a prescription and medical supervision. Talk to your physician before you start, change, or stop any medication.
Key facts at a glance
- 15-29% average weight loss, depending on the drug; bariatric surgery still produces more on average
- 20% fewer heart attacks, strokes, and cardiovascular deaths with semaglutide (SELECT trial)
- 24% fewer major kidney events in chronic kidney disease (FLOW trial)
- Up to 73% resolution of fatty liver disease (MASH) with tirzepatide
- 55-63% reduction in sleep apnea severity
- Fewer heavy drinking days in a randomized trial of semaglutide in alcohol use disorder
- 17% lower overall cancer risk in health-record studies; not yet tested in trials
- FDA-approved for obesity, type 2 diabetes, sleep apnea, MASH, and chronic kidney disease
- Much of the benefit does not come from the weight loss: heart protection starts before much weight is lost
The medicines in brief
GLP-1 medications are peptides that copy hormones the gut and pancreas release after a meal. They reduce appetite, make you feel full sooner, and improve blood sugar control. The class has been studied for two decades. Three drugs matter here:
| Drug | Brand names | Receptors | Status |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | GLP-1 | FDA-approved |
| Tirzepatide | Mounjaro, Zepbound | GLP-1 + GIP | FDA-approved |
| Retatrutide | none yet | GLP-1 + GIP + glucagon | Investigational; Lilly plans to file with the FDA in the first quarter of 2027 |
Tirzepatide produces more weight loss than semaglutide at similar rates of nausea, and retatrutide more again. See Weight loss and Side effects.
Supplies
Gather the supplies your prescribing clinician or care team asks for. The Supplies page gives neutral examples of each.
| Supply | Used for |
|---|---|
| Bacteriostatic water (USP, 0.9% benzyl alcohol) | Mixing the powder |
| 3 mL luer lock syringe with removable needles | Measuring and adding the water |
| Insulin syringes with fixed needles | Each weekly injection |
| Alcohol prep pads | Vial tops and skin |
| Sharps container | Used needles |
Bacteriostatic water quality varies. Buy USP bacteriostatic water from a licensed drug manufacturer. In one seller-commissioned lab test of 12 bacteriostatic water samples, 7 failed on benzyl alcohol content or pH, and 2 contained no benzyl alcohol at all. Sterile water without a preservative is for a single use, not for a vial you draw from for weeks. Buy the smallest vial you can: you use only a few mL before the 8-week limit.
Mixing your vial
Your medication arrives as a freeze-dried (lyophilized) white powder or puck in a small glass vial. Dry powder is stable for years. You mix it with bacteriostatic water once (reconstitution), keep the vial in the fridge, and draw each weekly dose from it.
How much water to add
The water you add sets the concentration, and the concentration sets how much liquid each dose is.
Concentration = mg of peptide in the vial ÷ mL of water added. Adding 3 mL of water to a 30 mg vial gives 10 mg/mL. Adding 1.5 mL to the same vial gives 20 mg/mL.
More water makes each dose a larger volume that is easier to measure. Less water makes each dose smaller but needs more precise measurement. Small starting doses need a dilute vial so each draw is large enough to read.
Insulin syringes are marked in units, and 100 units = 1 mL:
| Concentration | To inject 1 mg, draw | To inject 2 mg, draw |
|---|---|---|
| 5 mg/mL | 20 units | 40 units |
| 10 mg/mL | 10 units | 20 units |
| 20 mg/mL | 5 units | 10 units |
The Peptide calculator does this math for your vial and dose.
Steps
- Set up. Work on a clean, well-lit surface with all supplies ready.
- Remove the caps. Take the plastic caps off the peptide vial and the water vial. Leave the metal crimp and rubber stopper in place.
- Fill the syringe with air equal to the amount of water you will add.
- Draw the water. Swab the water vial top, insert the needle, push in the air, and draw out the water.
- Add it to the peptide vial. Swab the peptide vial top, insert the needle, and inject the water.
- Let it dissolve. Swirl gently and give it a few minutes.
- Dispose of the needle in your sharps container.
- Label and refrigerate. Write the date and concentration on the vial and put it in the fridge.
If the powder will not dissolve, wait a few more minutes and swirl again; if particles remain, discard the vial. The solution should be clear. If it turns cloudy, discard it.
What testing shows about research-grade vials
A purity result is the share of the peptide in a vial that is the correct molecule. It does not measure how much peptide the vial holds, whether it is sterile, or the weight of salts in the powder.
- Right molecule, often the wrong amount. A 2026 preprint analyzed 6,441 independently tested gray-market peptide samples (Finnrick data). Of samples with usable data, 97.6% contained the peptide on the label, and semaglutide, tirzepatide, and retatrutide typically had high purity. But fewer than one-third met both the purity and the fill standard (90-110% of label) that approved drugs must meet, and a little over half met the looser compounding-pharmacy standard (Mendias and Awan, preprint 2026).
- Overfilled vials. In one lab's 2025 testing, semaglutide vials averaged 116.8% and retatrutide vials 115.1% of the amount on the label, so a dose calculated from the label runs high. Some vials contained none of the peptide (Qualsera, Peptide Quality Index 2026).
- Sterility. In the same testing, 55 of 433 samples (12.7%) failed the USP sterility test. In the preprint, only 3.8% of samples had endotoxin testing; none exceeded 30 EU/mL, far below the limits for approved products.
- Salt forms. The FDA notes that semaglutide sodium and semaglutide acetate, which some sellers use, are different active ingredients from the one in approved semaglutide.
Injecting
GLP-1 medications go under the skin into fat (subcutaneous), not into muscle.
Sites. The abdomen is the most convenient (stay 2 inches away from the navel). The front or outer thigh and the back of the upper arm also work. Rotate sites each week to reduce irritation.
- Draw your dose. Swab the vial top, draw air equal to your dose, insert the needle, push in the air, and draw out your dose. Tap out any air bubbles.
- Clean the site with an alcohol pad and let it dry.
- Pinch a fold of skin if you are lean, so the dose goes into fat.
- Insert the needle fully, straight in at 90 degrees, or at 45 degrees if you are very lean.
- Push the plunger slowly and steadily.
- Count to 5 before you withdraw the needle.
- Dispose of the syringe in your sharps container. Press lightly if there is any bleeding.
Dosing
Standard FDA schedules
These are the label schedules. Our default is the low and slow schedule below: in trials, slower titration reduced nausea and dropouts without reducing results.
| Weeks | Semaglutide | Tirzepatide | Retatrutide (phase 3 trial schedule) |
|---|---|---|---|
| 1-4 | 0.25 mg | 2.5 mg | 2.0 mg |
| 5-8 | 0.50 mg | 5.0 mg | 4.0 mg |
| 9-12 | 1.0 mg | 7.5 mg | 6.0 mg |
| 13-16 | 1.7 mg | 10.0 mg | 9.0 mg |
| 17-20 | 2.4 mg | 12.5 mg | 12.0 mg |
| 21 and after | 2.4 mg | 15.0 mg | 12.0 mg |
Retatrutide. In the phase 3 trials, 4 mg and 9 mg were also target doses: the 4 mg group stopped after one step, and the 9 mg group after three. Lighter people, often women, do better starting at 1 mg: practitioners and users find 2 mg too strong a first dose for many of them, and in the phase 2 trial even a fixed 1 mg dose produced 8.7% weight loss at 48 weeks.
Wegovy HD (approved March 2026). After at least 4 weeks on 2.4 mg, the label allows an increase to 7.2 mg weekly when more weight loss is clinically indicated. In STEP UP, 7.2 mg produced 18.7% loss against 15.6% on 2.4 mg, at a cost: stomach side effects in 70.8% versus 61.2%, and tingling or altered skin sensation (dysesthesia) in 22.9% versus 6.0% (Lancet Diabetes Endocrinol 2025). That is three times the peptide for 3 more percentage points; tirzepatide reaches more at lower side-effect rates.
Low and slow titration
Slower titration reduces side effects. In a 104-person randomized trial in type 2 diabetes, a slower semaglutide titration cut nausea days from 6.3 to 2.9 and withdrawals for stomach side effects from 19% to 2%, with similar weight and blood sugar results (Eldor et al., Diabetes Care 2025). Tirzepatide's trials showed the same pattern when its starting dose and steps were made smaller (SURPASS-2). A 2026 analysis across the approved drugs found that longer escalation with more steps builds tolerance: the dose at which half of people get nauseous was higher in the phase 3 trials (with escalation) than in phase 1 trials (without), and the drugs with longer, multi-step escalation reached higher doses and larger effects (Nauck, Diabetes Obes Metab 2026). Slower titration delays weight loss; it does not reduce the weight lost once a dose is reached and held.
Tirzepatide or retatrutide (our default). Start at 0.5 mg a week and increase by 0.25-0.5 mg each week until you reach your effective dose. This starts lower and steps up in smaller increments than the trials did, because every trial that compared escalation speeds found slower escalation gentler without less final weight loss, and practitioners and users report that this schedule works well.
| Week | mg/week | Week | mg/week |
|---|---|---|---|
| 1 | 0.50 | 11 | 4.00 |
| 2 | 0.75 | 12 | 4.50 |
| 3 | 1.00 | 13 | 5.00 |
| 4 | 1.25 | 14 | 5.50 |
| 5 | 1.50 | 15 | 6.00 |
| 6 | 1.75 | 16 | 6.50 |
| 7 | 2.00 | 17 | 7.00 |
| 8 | 2.50 | 18 | 7.50 |
| 9 | 3.00 | 19 | 8.00 |
| 10 | 3.50 |
Semaglutide. This is the slow arm of the Eldor trial: start at about 0.07 mg (0.0675 mg in the trial) and add about 0.07 mg each week. It reaches 1 mg around week 15, against week 9 on the label schedule. At 1 mg/mL (for example, 2 mg of semaglutide in 2 mL of water), 0.07 mg is a 7-unit draw.
| Week | 1 | 2 | 3 | 4 | 6 | 8 | 10 | 12 | 15 |
|---|---|---|---|---|---|---|---|---|---|
| mg/week | 0.07 | 0.14 | 0.20 | 0.27 | 0.41 | 0.54 | 0.68 | 0.81 | 1.00 |
Rules for any schedule:
- Hold when side effects appear. If a dose feels uncomfortable, stay there or drop back slightly until it settles, then continue.
- Find your effective dose. Not everyone needs the maximum; many people plateau at a moderate dose.
- Split dosing is an option. Some people tolerate the drug better as two half-doses a week (for example, 2 mg twice a week instead of 4 mg once), which smooths out blood levels.
Eating and training on therapy
Smaller meals mean most people unintentionally take in fewer vitamins, minerals, and fiber. These habits protect your nutrition and your lean mass.
Protein and strength training
The share of lean versus fat lost is similar to, or modestly higher than, dieting alone. A 2026 review of 35 trials found that a median of about 29% of the weight lost was lean tissue on DEXA or bioimpedance, with the middle half of studies between about 17% and 43%, against a benchmark of about 25% for weight loss in general (Batsis, Annals of Internal Medicine 2026). DEXA lean mass includes organs and water, not only muscle: in mice on these drugs the liver shrank proportionally more than muscle, and strength held up in a small human trial (Langer, Cell Reports Medicine 2026). To keep the loss small:
- Strength train 2-3 times a week, covering the major movement patterns.
- Eat 0.7-1.0 g of protein per lb of goal body weight a day, and treat it as your first priority at each meal. A 2024 review suggests at least 1.2 g/kg a day during weight loss, calculated on goal weight when current weight makes that hard to reach (Tinsley & Heymsfield 2024).
Vitamins, fiber, and fluids
- Multivitamin. Take a good-quality multivitamin daily (for example, Thorne Basic Nutrients 2/Day). A significant share of long-term users develop at least one nutrient deficiency.
- Fiber. Take psyllium husk: start at 3-5 g a day and build to about 10 g. Take it with plenty of fluid and at least 2 hours apart from other medications, since fiber can reduce their absorption. Keep your total at 25 g a day or more (women) or 30 g (men), food plus psyllium (ACC 2026 scientific statement).
- Fluids. Aim for 2-3 L a day; thirst can be blunted on these medications.
- Steps. Keep 7,000-10,000 steps a day as a baseline.
Side effects
The most common side effects are nausea, constipation, and diarrhea. They typically occur during dose escalation and resolve within 1-2 weeks, and slower titration greatly reduces them.
The drugs differ. In the head-to-head SURMOUNT-5 trial, at maximum tolerated doses, nausea, diarrhea, and constipation rates were similar for tirzepatide and semaglutide (nausea 43.6% vs 44.4%). Tirzepatide produced substantially more weight loss at those rates, about half the stomach-related discontinuations (2.7% vs 5.6%), and less vomiting (15.0% vs 21.3%). Matched for weight loss, tirzepatide and retatrutide are much gentler than semaglutide for most people. Based Health's experience with dozens of clients, other practitioners' and users' reports, and these trial results agree; retatrutide has no head-to-head trial. Retatrutide's side effects rise with dose. In the published TRIUMPH-1 paper, 4.1%, 6.5%, and 11.1% stopped for side effects on 4, 9, and 12 mg (4.6% on placebo), so the lower doses were well tolerated. In TRIUMPH-4, dysesthesia (tingling, burning, or skin sensitivity) affected 8.8% on 9 mg and 20.9% on 12 mg, against 0.7% on placebo. Switching drugs can help if one isn't tolerated.
| Problem | What helps |
|---|---|
| Nausea | Eat smaller, more frequent meals. Avoid high-fat foods, which slow stomach emptying further. Stay upright for 30 minutes after eating. If it persists after a dose increase, drop back to the last tolerated dose for 2 or more weeks before trying again, and consider smaller steps (0.25 mg instead of 0.5 mg). |
| Constipation | Take psyllium from the start, drink at least 2-3 L a day, and stay active. Magnesium citrate if needed. |
| Injection site redness, itching, or swelling | Common and usually mild. Rotate sites and ice the area first if sensitive. It usually fades with continued use. |
Hair shedding
GLP-1 drugs raise the chance of diagnosed hair loss, mostly diffuse non-scarring shedding. In about 24,000 adults with type 2 diabetes it ran about 7 vs 5 cases per 1,000 person-years against SGLT-2 drugs (BMJ 2026), roughly 1 extra case per 100 people over five years. Shedding usually follows rapid weight loss and low intake, starts a few months in, and regrows once weight and intake settle. Protect protein and total energy intake, check ferritin if shedding starts, and slow titration if intake has dropped sharply.
Hormonal contraception
Tirzepatide slows stomach emptying and lowers the amount of oral contraceptive absorbed. The Zepbound label advises people using oral hormonal contraception to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. The same caution is reasonable for retatrutide, which has no label.
Missed doses
Follow the drug's FDA label:
- Semaglutide (Wegovy label): if the next dose is more than 2 days away, take the missed dose as soon as possible; if it is within 2 days, skip it and take the next dose on the usual day. (The Ozempic label states the same window as "within 5 days after the missed dose.")
- Tirzepatide (Zepbound label): take the missed dose within 4 days (96 hours); after that, skip it and resume on the usual day.
- Retatrutide has no label; the tirzepatide rule is a reasonable stand-in.
- Two or more weekly doses missed (any of these drugs): restart at a lower dose and step back up. The Wegovy label says to restart the escalation at a lower dose after 2 or more missed doses, to reduce stomach side effects, and users who dose only once a month report the same stomach problems. The Zepbound label has no rule for gaps this long; use the same approach.
- Never double up, and keep doses at least 3 days apart.
Storage and shelf stability
GLP-1 peptides are stable when stored well; claims of short shelf lives are often exaggerated.
| Form and place | How long it keeps |
|---|---|
| Powder, frozen (-20°C or below) | 5 years or more. Best for long-term storage. |
| Powder, refrigerated (2-8°C / 36-46°F) | 2 years or more |
| Powder, room temperature (20-25°C / 68-77°F) | Several months; fine for shorter periods |
| Mixed vial, refrigerated | Use within 8 weeks of the first puncture |
| Mixed vial, at room temperature | Tirzepatide is labeled for up to 21 days below 30°C (86°F) and semaglutide for 28 days below 30°C. Fine for travel; refrigerate otherwise. |
| Mixed vial, frozen | Do not freeze. Freezing and thawing damages the molecule. |
| Bacteriostatic water, opened | Discard 8 weeks after first puncture. Refrigerate it and swab the top before every needle. |
For stockpiling, keep vials frozen and unmixed. For active use, keep the mixed vial in the fridge.
Why the powder lasts
Novo Nordisk's regulatory data show bulk semaglutide stable for 60 months at -20°C or below (EMA Wegovy assessment report). The approved liquid pens of tirzepatide and semaglutide are labeled for 24 months in the fridge, and dry powder is at least as stable as liquid.
Why a mixed vial has an 8-week limit
Two separate questions: does the peptide stay potent, and does the vial stay clean? The peptide holds up for months in the fridge; contamination is the main risk.
Potency:
- Semaglutide: no regulator has tested powder mixed with bacteriostatic water. The approved pens stay in specification for 28 days at up to 30°C once in use (EMA Wegovy assessment report), so a refrigerated vial is expected to hold for months, as tirzepatide does.
- Tirzepatide: Lilly's formulation data show the intact peptide going from 99.35% to 98.81% over 3 months at 5°C (US11357820B2).
- Retatrutide: no manufacturer or regulator data yet, since it is not approved. In independent lab tests (HPLC) of reconstituted vials kept at 4°C, most still held about 90-98% of their starting peptide at 60-90 days; one vial of seven lost about half for no known reason (PTDS, September 2026). Frozen-and-thawed vials kept about 86% at 45 days, against 90-91% for refrigerated vials at 90 days. One tester reported no measurable drop after six months refrigerated (Cremieux Recueil, "How To Get Cheap Ozempic"). Retatrutide is built like tirzepatide and semaglutide, so similar stability is expected, but plain bacteriostatic water is not an optimized formulation and research-grade vials vary in starting quality.
Contamination. Each puncture can carry in bacteria, and refrigeration slows their growth but does not stop it; the 0.9% benzyl alcohol in bacteriostatic water slows it too, but does not stop it either. The 28-day discard rule in CDC and USP <797> guidance was written for healthcare settings, where a vial may serve many patients and be punctured many times a day. A vial one person punctures once a week carries far less risk, and potency is not the limit. Our limit is 8 weeks, on these conditions: keep it in the fridge, swab the top before every draw, use a new needle every time, and throw it away if it turns cloudy or shows particles. What is unknown: no study has measured contamination in single-user vials over 8 weeks. User reports (no injuries among 321 subscribers of one writer who used vials for up to nine months) are reassuring, but they cannot show that a rare infection never happens.
Maintenance dosing
The default is continuing, not stopping. After reaching your target weight, the usual approach is to keep the medication at the lowest dose that holds the result. The benefits go beyond weight (heart, kidney, inflammation; see Benefits beyond weight loss), and the lean-mass concern is managed with strength training, protein, and creatine rather than by stopping. Stopping makes sense for stomach side effects that slower titration and a switch of drug do not fix, for lean-mass loss that continues despite training and protein, or by your own informed choice.
Ways to continue
Each of these holds most of the loss. Choose by cost, side effects, and how much of the loss you want to hold.
A lower weekly dose. Step down from the dose that got you there to a maintenance dose (for example, 4 mg down to 1 mg). In SURMOUNT-MAINTAIN, after 60 weeks of tirzepatide, continuing the maximum tolerated dose, stepping down to 5 mg, or switching to placebo gave total weight change at week 112 of −21.9%, −16.6%, and −9.9%. On 5 mg, 25% of people regained enough to need rescue treatment, against 8% on the full dose. A reduced dose preserves most of the loss; placebo preserves under half.
Every-other-week dosing. Keep the same dose but inject every other week. These drugs last about a week in the body (half-lives of 5 to 7 days), so a level remains between doses. A pharmacokinetic model estimates that every-other-week dosing keeps about 75% of the weight-loss effect, and close to all of it if the dose is raised to match (Diabetes Obes Metab 2025). In a 30-person case series, people who had plateaued on weekly semaglutide or tirzepatide moved to every-other-week dosing for an average of 36 weeks and held their weight (74.1 kg at plateau, 72.4 kg on maintenance), with fat still falling, muscle mass stable, and blood sugar, triglyceride, and blood pressure gains kept (Obesity 2026). Practitioners and users report the same.
Whichever you choose, keep protein at 0.7-1.0 g/lb of goal weight and keep strength training.
If you stop
- Taper. Reduce the dose over several weeks rather than stopping at once; this may hold results better.
- Keep the habits. Protein, strength training, fiber, and steps continue after the drug stops.
- Phentermine is one option. In Epic Research health records (7,773 patients, 2024), fewer of those who started phentermine regained all their GLP-1 loss within a year (19.3% versus 27.3%), but phentermine helped least for people who had lost the most: more than half of those who had lost 20 pounds or more regained some or all of it. Phentermine's label rules it out with heart disease, arrhythmias, uncontrolled high blood pressure, hyperthyroidism, glaucoma, or a history of drug misuse.
- Craving effects fade within days. Any reduction in cravings for alcohol or other substances reverses soon after the last dose.
What happens to weight after stopping
- Randomized trials: most of the loss returns within a year. One year after stopping semaglutide in the STEP 1 extension, people had regained about two-thirds of what they lost (net loss fell from 17.3% to 5.6%). In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, ending 9.9% below their starting weight.
- Pooled trials agree. A 2025 meta-analysis of 18 randomized trials found an average regain of 5.6 kg after stopping, with waist, blood pressure, and blood sugar worsening too (Tzang, eClinicalMedicine 2025). A 2026 BMJ review of 37 studies found regain of about 0.8 kg (1.8 lb) a month after semaglutide or tirzepatide, projecting a return to starting weight about 1.5 years after stopping; after any weight-loss drug, blood sugar, blood pressure, and cholesterol returned to baseline within about 1.4 years (West, BMJ 2026).
- Real-world records are more hopeful. About 55% were at or below their stopping weight two years after stopping (Epic Research 2025, 188,722 patients: semaglutide 56.1%, tirzepatide 55.2%, liraglutide 51.9%), and 21-27% regained everything (tirzepatide 21%, semaglutide 23%, liraglutide 27%); the pattern largely stabilized after the first year. This is observational, and people who restarted a GLP-1 or another weight-loss treatment were removed from follow-up.
What to expect
Most people notice appetite changes within the first week. The main effect is quieter "food noise": the constant mental chatter about food fades. Thoughts about eating come when you are truly hungry and fade after a satisfying amount. In a 6-week randomized trial, by week 3 people on tirzepatide ate about 525 kcal less than those on placebo at a lunch where they could eat as much as they liked, and they reported less hunger, fewer food cravings, and less tendency to overeat (Martin, Nature Medicine 2025). People commonly report:
- Less preoccupation with food, which frees up mental bandwidth
- Eating from hunger rather than habit or emotion
- Feeling satisfied with smaller portions without a fight
- Less pull toward hyperpalatable foods and alcohol
One way to think about these drugs: they increase your capacity for behavior change.
What to monitor
While on therapy, check periodically:
- Weight and body composition
- Stomach tolerance
- Mood. Tell your prescriber about any low mood or loss of interest or pleasure in things (anhedonia).
- Nutritional status, with periodic bloodwork if you stay on therapy long term
- Ferritin (iron stores) before starting and again 3-6 months in. Eating less means taking in less iron: in one food-record study, people on these medications averaged 12 mg of iron a day, below the recommended intake (Johnson, Frontiers in Nutrition 2025). Based Health aims for a ferritin of at least 50 ng/mL, or at least 60 for people who menstruate, train for endurance, or plan a pregnancy, well above many labs' lower limit. Studies have not yet shown that the drugs themselves cause iron deficiency, and a low result needs its cause found before taking iron.
What the evidence shows
Weight loss
Semaglutide produces 15-17% average weight loss and tirzepatide 20-21%. Retatrutide's highest dose produced 25.0% at 80 weeks counting everyone randomized, or 28.3% had everyone stayed on treatment, in the published TRIUMPH-1 trial, with some participants losing over 30%.
Bariatric surgery still produces more on average. A 2026 network meta-analysis of 30 randomized trials found surgery took off about 10 percentage points more body weight than GLP-1 drugs as a class, though the gap with tirzepatide alone was not statistically significant (Sabatella, Obesity 2026). In a US insurance cohort with class II or III obesity, total weight loss was 28.3% after surgery and 10.3% on GLP-1 drugs (Barrett, JAMA Surgery 2025). Retatrutide's highest dose roughly matches surgery's range.
Body composition. Waist reductions of 5-8 inches are typical, and visceral fat falls disproportionately. For retatrutide, a phase 2 substudy in type 2 diabetes measured body composition by DEXA at 36 weeks: fat mass fell by up to 26%, and the share of weight lost as lean mass was similar to other obesity treatments (Coskun, Lancet Diabetes & Endocrinology 2025). Body-composition results from the phase 3 trials are not in the published TRIUMPH-1 or TRIUMPH-2 abstracts.
Metabolic health. Blood sugar improves within weeks, insulin sensitivity improves, and inflammatory markers fall, often before much weight is lost.
Benefits beyond weight loss
A large share of what these medications do for the heart, kidneys, and liver does not come from the weight loss, and the trials now measure how much. In SELECT, an estimated 33% of the cardiovascular benefit was attributed to the reduction in waist circumference; the other two-thirds was not explained by any change in weight or waist, and the benefit was the same whatever the starting weight. In FLOW, weight loss explained none of the kidney benefit (an estimated −0.5%). In the MASH phase 2 trial, weight loss explained 69% of the resolution of steatohepatitis but only 25% of the improvement in fibrosis. A one-year kidney-biopsy trial (REMODEL) then showed the mechanism directly: less vascular resistance, fewer immune cells around the glomerular capillaries, and stabilized fibrosis markers.
Based Health's reading of the whole picture is that the class acts directly on blood vessels, kidney, liver, and inflammation, and that the share of each benefit that survives after accounting for weight has grown with every analysis done so far. That is why the maintenance dose is a long-term medicine, not a short course that ends when the scale says so. The grades below separate what is established from what is early.
| Benefit | What the evidence says about weight | Grade | Source |
|---|---|---|---|
| Cardiovascular events (SELECT, 17,604 people) | 20% fewer heart attacks, strokes, and cardiovascular deaths; an estimated 33% of the benefit mediated by waist reduction, so about two-thirds not explained by adiposity change; benefit consistent across baseline weight and waist categories | Established (randomized trial, prespecified mediation analysis) | Deanfield, Lancet 2025 |
| Early cardiovascular benefit (SELECT) | 37% fewer events in the first 3 months, before meaningful weight loss and before most people reached full dose | Established outcome, post hoc timing analysis | Arch Cardiovasc Dis 2026 |
| Kidney outcomes (FLOW, 3,533 people with type 2 diabetes and CKD) | 24% fewer major kidney events, 20% lower all-cause mortality; weight change mediated an estimated −0.5% of the kidney outcome (−33% of cardiovascular events, −26% of deaths); effect consistent across baseline BMI | Established outcome; mediation is an exploratory conference analysis | FLOW, NEJM 2024; Mann, ADA 2025 abstract 1971-LB |
| Kidney tissue (REMODEL, 106 people, 52 weeks) | Biopsy and MRI: lower renal artery resistive index, stabilized diffusion coefficient (fibrosis progression prevented), fewer immune cells next to glomerular endothelial cells; the coprimary MRI outcomes (oxygenation, perfusion, T1 inflammation) did not reach significance | Established as a mechanism signal; small trial | Tuttle, Nature Medicine 2026 |
| Liver (MASH) | Phase 2 (320 people): weight loss mediated 69% of steatohepatitis resolution, 83% of steatosis improvement, and 25% of fibrosis improvement; serum proteomics showed inflammatory and fibrotic pathway changes partly separate from weight; liver cells do not carry GLP-1 receptors, so the action is indirect. ESSENCE phase 3 secondary analysis: histology and non-invasive test responses only partly mediated by weight | Established outcome; mediation exploratory | Jara, Nature Medicine 2025; Newsome, AASLD 2025 secondary analysis of ESSENCE |
| Proteomic organ age (SELECT, STEP-HFpEF, STEP-HFpEF DM, FLOW, SOUL; 10,052 people, up to 156 weeks) | Heart biological age 2 to 4 years lower than placebo in all five trials, with 1 to 4 year reductions in kidney, brain, pancreas, lung, and multi-organ clocks; most heart and kidney changes not mediated by weight, HbA1c, or CRP. Heart signal rests largely on lower NPPB (BNP); the adipose clock read older early on because leptin fell with fat loss | Early (preprint, not peer reviewed, Novo Nordisk-authored) | Dermit, Research Square 2026 |
| Knee cartilage | Semaglutide protected cartilage in obese mice with diet-controlled (pair-fed) comparison to rule out weight loss, through a GLP-1R-AMPK-PFKFB3 chondrocyte metabolism pathway; a randomized human pilot supports it | Early (animal mechanism plus a pilot) | Qin, Cell Metabolism 2026 |
| Psoriasis and psoriatic arthritis | Tirzepatide added to ixekizumab: PASI 100 in 40.6% vs 29.0% (psoriasis, 274 people); ACR50 in 33.5% vs 20.4% (psoriatic arthritis, 271 people) with separation at week 4 | Early (open-label phase 3b combination trials; weight-mediation not analyzed) | Lebwohl, JAMA Dermatology 2026; Merola, Arthritis & Rheumatology 2026 |
| Mood, anxiety, substance use | In 63,215 people with existing neuropsychiatric conditions, higher attained semaglutide dose, not amount of weight lost, predicted fewer mood, anxiety, and substance-related diagnoses over the following two years | Early (observational records) | Murugadoss, npj Metabolic Health and Disease 2026 |
| Asthma and COPD | UK records, four parallel studies of 20,000 to 22,000 people each vs sulfonylurea: nearly 40% fewer asthma attacks and 20% fewer COPD flares with semaglutide | Early (observational, conference presentation, no weight adjustment reported) | Bloom, ERS Congress 2026 |
One caveat applies to every percentage in the table: a mediation analysis cannot fully separate weight from drug effects. Weight loss is itself a drug effect, the confidence intervals are wide, and a mediator the trial did not measure is invisible to it. The percentages are estimates of how much of the benefit the weight change can account for, not proof of what the rest is.
Heart and blood vessels
In SELECT, semaglutide cut major cardiovascular events (heart attack, stroke, cardiovascular death) by 20%, and the benefit appeared early: 37% fewer events over the first 3 months (HR 0.63, 0.41-0.95), before meaningful weight loss and before most people reached the full dose (SELECT early-benefit analysis, Archives of Cardiovascular Diseases 2026).
- Heart failure. In heart failure with preserved ejection fraction (HFpEF), these medications show a 40% reduction in heart failure events. In heart failure with reduced ejection fraction (HFrEF), use them cautiously because of increased heart rate and arrhythmia signals.
- Blood pressure and lipids. Systolic blood pressure drops 7-14 mmHg, enough that 30-41% of retatrutide trial participants stopped at least one blood pressure medication. Triglycerides fall 24-40%, LDL 12-22%, and ApoB 8-24%. Semaglutide also lowers atrial fibrillation risk by 17-42%; tirzepatide does not show this effect.
- Retatrutide and heart rate. In the phase 2 trial, retatrutide's glucagon component raised heart rate by 5-10 bpm (roughly twice that of other agents), peaking at 24 weeks and then partly declining. The TRIUMPH-OUTCOMES trial (~10,000 participants, 5 years) will show whether this matters clinically.
Kidneys
In January 2025, semaglutide was FDA-approved to slow kidney disease progression, making GLP-1 drugs the "fourth pillar" of chronic kidney disease treatment alongside ACE inhibitors, SGLT2 inhibitors, and finerenone. The FLOW trial was stopped early for efficacy: 24% fewer major kidney events, 20% lower all-cause mortality, and 29% lower cardiovascular death. The number needed to treat to prevent one death is 39 over 3 years. Benefits add to existing treatments and are consistent across disease severity and baseline BMI.
Liver (MASH)
In August 2025, semaglutide became FDA-approved for MASH (formerly NASH), a condition that previously had almost no effective treatments. In the ESSENCE trial, 62.9% of participants achieved MASH resolution at 72 weeks, and 36.8% had improved fibrosis (liver scarring). Tirzepatide reached 73.3% resolution in SYNERGY-NASH, the highest for any agent to date. Retatrutide reduced liver fat by 82-86%, with 93% reaching normal liver fat levels. MASH affects 5% of adults and is projected to become the leading cause of liver transplantation.
Joints (osteoarthritis)
GLP-1 medications reduce osteoarthritis pain, and animal studies suggest effects beyond reduced load on the joint; whether they slow joint damage in humans is not yet shown.
- Pain. In the STEP 9 trial, semaglutide improved knee pain scores by 14 points more than placebo. In two retatrutide trials (TRIUMPH-4 and TRIUMPH-1-OA, NEJM 2026; 1,019 adults), knee pain improved by 1.4 to 1.8 points on a 10-point scale more than placebo, while placebo itself improved about 2 points. Weight fell 20% to 24% at 68 weeks in TRIUMPH-4, serious side effects were more common than on placebo, and the trials do not show pain relief beyond what the weight loss explains.
- Surgery. Meta-analyses show a 25% lower likelihood of knee replacement in GLP-1 users, with only about one-third of that benefit attributable to weight loss. For people who do need a joint replacement, GLP-1 use before surgery is linked to 42% lower prosthetic infection risk and 47% fewer 90-day readmissions.
- Mechanism. A 2025 Science paper described a gut-joint axis: GLP-1 receptors in cartilage reduce inflammation and cartilage-degrading enzymes. In a March 2026 Cell Metabolism study (Qin et al.), mice given semaglutide had cartilage protection that pair-fed mice losing the same weight without the drug did not, through the GLP-1R-AMPK-PFKFB3 pathway, which shifts cartilage cells from glycolysis to more efficient oxidative phosphorylation. Removing either the GLP-1 receptor or AMPK abolished the effect. In a small human trial (20 participants, 24 weeks), cartilage thickened by ~17% on MRI with semaglutide versus under 1% with standard treatment alone.
- Earlier human data. The Shanghai Osteoarthritis Cohort found slower cartilage loss on MRI in GLP-1 users after adjusting for weight change and blood sugar, and a retrospective study of 39,394 patients found tirzepatide associated with 43% lower osteoarthritis risk than semaglutide.
- Still unknown. Whether the mechanism applies to retatrutide's pain results is untested, and cartilage regeneration in humans is unconfirmed. The STOP-KNEE OA trial (NCT06191848) is testing tirzepatide with structural MRI endpoints.
Sleep apnea
Tirzepatide became the first FDA-approved medication for obstructive sleep apnea in December 2024. In the SURMOUNT-OSA trials, apnea severity fell 55-63% (27-30 fewer events per hour). Many participants moved from severe to mild, with better oxygen levels, less daytime sleepiness, and blood pressure about 5 mmHg lower, whether or not they used CPAP.
Brain and mood
Dementia. GLP-1 users show a 33-46% lower risk of Alzheimer's disease in observational studies, most strongly for vascular dementia. But the EVOKE trials found that semaglutide did not slow decline in early symptomatic Alzheimer's. A 2026 review in Science explains how both can be true: in people with metabolic disease, most of any brain benefit probably comes indirectly, through healthier blood vessels, blood sugar, sleep, and fitness. Slowing a disease already under way would need the drug to act on the brain itself, and it is unclear how much of it gets there. Any benefit is likely to come from treating metabolic disease early, before neurodegeneration is established.
Migraine. In a pilot study, monthly headache days fell from 19.8 to 10.7, about 9 fewer a month.
Mood. The randomized evidence does not show psychiatric harm. Across 80 placebo-controlled trials (107,860 people with obesity or diabetes), GLP-1 drugs did not raise serious or nonserious psychiatric adverse events or worsen depressive symptoms, and they slightly improved mental and physical quality of life and emotional eating (Pierret 2025). Many trials excluded people with active psychiatric illness. For that group, a Swedish register study of about 95,000 people with depression or anxiety, each compared on and off the drug, found 42% less worsening of mental illness during semaglutide use (44% depression, 38% anxiety) and 18% less with liraglutide (Taipale 2026); this is observational, mostly in people with diabetes, and time-varying confounding is possible. The earlier depression signal came from pharmacovigilance and case reports. In January 2026 the FDA asked the makers of Wegovy, Zepbound, and Saxenda to remove the suicidal-ideation warning from their labels, after its meta-analysis of 91 placebo-controlled trials (107,910 people) found no increased risk of suicidal thoughts or behavior.
Alcohol, nicotine, and other cravings
GLP-1 medications blunt the dopamine spikes that drugs and drug cues trigger in reward circuits, while leaving normal pleasure and motivation intact.
Alcohol. The first GLP-1 trial in alcohol use disorder tested exenatide (Klausen et al., JCI Insight 2022; 127 treatment-seeking patients, 26 weeks): it did not reduce heavy drinking days overall, though an exploratory subgroup with BMI over 30 drank less. The first semaglutide trial (Hendershot et al., JAMA Psychiatry 2025; 48 non-treatment-seeking adults, 9 weeks, low doses up to 1.0 mg) found semaglutide reduced drinks per drinking day, weekly craving, and alcohol consumed in a laboratory self-administration task, with medium-to-large effect sizes, but did not change the number of drinking days or average drinks per day. The first full-dose trial followed in 2026 (SEMALCO; Klausen et al., Lancet): 108 people seeking treatment for alcohol use disorder who also had obesity took semaglutide 2.4 mg or placebo for 26 weeks, alongside counselling. Heavy drinking days fell 41 percentage points on semaglutide versus 26 on placebo. Observational data also suggest fewer alcohol-related hospitalizations among GLP-1 users. Semaglutide is not approved for alcohol use disorder, and no trial has yet compared it with existing treatments such as naltrexone.
Opioids. Liraglutide reduced opioid cravings by 40% in a small trial, and population data from ~500,000 patients linked GLP-1 use with 40% lower overdose rates. Larger trials are underway.
Nicotine. Results are mixed: the drugs do more to prevent weight gain after quitting than to help people quit. In a small 2026 trial in daily smokers, semaglutide reduced craving but not the number of cigarettes smoked (Hendershot, JAMA Network Open). Behavioral addictions have no trial data yet.
Cancer
A 2025 JAMA Oncology study found GLP-1 users had 17% lower overall cancer risk. Liver cancer shows the strongest signal (58-59% lower risk). Colorectal cancer risk is 18-43% lower, with 56% lower 5-year mortality among colon cancer patients. Endometrial cancer is 25% lower and ovarian cancer 47%. Kidney cancer results depend on the comparison: 38% higher than in non-users in the JAMA Oncology study (HR 1.38, 0.99-1.93), 54% higher than metformin but 24% lower than insulin in people with diabetes (Wang, JAMA Network Open 2024), and no clear difference in placebo-controlled trials (odds ratio 1.12, 0.78-1.60; Ko 2026). The mechanism is unclear. Pancreatic cancer shows no association.
How to read these numbers. Almost all of these figures come from health records, not trials. A health-record study measures everything that comes with starting the drug: weight loss, often less smoking and drinking, better eating and activity, and more doctor visits and cancer screening. More screening can even raise the number of cancers found, or find them earlier. These studies cannot say how much of the benefit comes from the drug itself (Hicks and Pottegård, Science 2026). Treat cancer prevention as a promising possibility, not a reason to start the medication, and keep up your usual screening.
Safety
Who should not use them
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia type 2 (MEN2)
- Known allergy to the medication
- Past pancreatitis: use with caution, and tell your prescriber
Rare risks
Thyroid cancer. The rodent signal has not appeared in humans: there was no detectable excess in a cohort of 460,032 GLP-1 users compared against three other diabetes drugs (Morales, Diabetes Care 2025) or in 48 placebo-controlled trials (odds ratio 1.37, 0.82-2.31, an imprecise estimate; Ko, Annals of Internal Medicine 2026). These studies report thyroid cancer overall; medullary thyroid cancer, the rare type seen in rodents, remains untested on its own, so the contraindication above stands.
Pancreatitis. Placebo-controlled trials show no excess with semaglutide or tirzepatide: 59 cases in 22,841 people on drug and 50 in 17,433 on placebo across 31 trials (OR 0.99, 0.67-1.45; Bakker 2026, preprint), and tirzepatide shows no dose-response from 5 to 15 mg. A broader 2025 meta-analysis of 62 trials across the class (66,232 people) found a slight increase (RR 1.44, 1.09-1.89) that was no longer significant when trials were split by background medication (Wen 2025). In January 2026 the UK regulator (MHRA) strengthened the class warning after rare necrotising and fatal cases: 19 of 1,296 UK pancreatitis reports since 2007 were fatal. Events are rare enough that a small effect cannot be ruled out, so the label warning stands.
Gallstones. Risk rises a little on these drugs, more at weight-loss doses and with longer use, and rarely becomes serious: in 76 placebo-controlled trials it was 1.27 times placebo in diabetes trials and 2.29 times in weight-loss trials (He, JAMA Internal Medicine 2022).
Bowel blockage (ileus). In people with diabetes, health records show less ileus than in those not on a GLP-1 (Epic Research 2024). Constipation itself is common (see Side effects).
Sudden vision loss (NAION). This optic-nerve stroke, nicknamed "Ozempic blindness," was raised by a 2024 single-clinic study. Pooled data from 112 placebo-controlled liraglutide and semaglutide trials (96,829 people) found 3 confirmed cases on drug and 5 on placebo (Vilsbøll 2026; manufacturer-run). European regulators still list it as a very rare side effect. Sudden painless vision loss in one eye needs same-day assessment.
If you have diabetes
People with diabetes typically lose less weight and may lose more lean mass, which makes strength training more important. Severe complications such as worsening retinopathy occur almost only in people with diabetes whose blood sugar falls too quickly.
References
Storage and stability
- FDA Tirzepatide Approval Letter
- EMA Tirzepatide Assessment Report
- EMA Semaglutide Assessment Report
- Tirzepatide Stability Patent Data
- Tirzepatide Formulation Stability - US11357820B2
- Retatrutide Reconstituted Stability Tests - PTDS 2026
Product quality
- Peptide Quality Index 2026 - Qualsera
- Research-Grade Peptides Marketed to Consumers, Purity and Fill (Mendias and Awan) - preprint 2026
- FDA's Concerns With Unapproved GLP-1 Drugs, Including Salt Forms - FDA
Dosing, titration, and labels
- Gradual Titration of Semaglutide - Diabetes Care 2025
- SURPASS-2 Titration Analysis - NEJM
- Dose-Escalation Regimens and Tolerance for Nausea and Vomiting (Nauck) - Diabetes Obes Metab 2026
- STEP UP: Semaglutide 7.2 mg - Lancet Diabetes Endocrinol 2025
- Wegovy Prescribing Information, including Wegovy HD 7.2 mg - DailyMed
- Wegovy HD 7.2 mg FDA Approval - Novo Nordisk, March 2026
Retatrutide
- TRIUMPH-1: Retatrutide for Obesity - NEJM 2026
- TRIUMPH-1 Topline Results, Dosing Schedule, and Adverse Events - Lilly, May 2026
- TRIUMPH-2: Retatrutide in Obesity and Type 2 Diabetes - Lancet 2026
- TRIUMPH-2 and TRIUMPH-3 Topline Results and FDA Filing Plan - Lilly, July 2026
- Retatrutide Phase 2 Trial - NEJM 2023
- Retatrutide Body Composition Substudy (Coskun) - Lancet Diabetes Endocrinol 2025
Nutrition, body composition, and appetite
- Body Composition With Incretin-Based and Nonpharmacologic Weight Loss, Systematic Review (Batsis) - Ann Intern Med 2026
- GLP-1 Medicines and Muscle Mass and Function in Mice and Humans (Langer) - Cell Rep Med 2026
- Body Composition Principles and Protein Targets With GLP-1 RAs (Tinsley & Heymsfield) - J Endocr Soc 2024
- Tirzepatide and Ingestive Behavior, 6-Week RCT (Martin) - Nature Medicine 2025
Maintenance and stopping
- SURMOUNT-MAINTAIN Results - Lancet 2026
- SURMOUNT-MAINTAIN Trial Design - Obesity 2025
- Alternative Dosing Regimens, PK/PD Modeling Study - Diabetes Obes Metab 2025
- Reduced-Frequency GLP-1 Therapy Maintains Weight, 30-Person Case Series - Obesity 2026
- SURMOUNT-4 - JAMA 2024
- STEP 1 Trial Extension: Regain After Stopping Semaglutide - Diabetes Obes Metab 2022
- Metabolic Rebound After Stopping GLP-1 RAs, Meta-Analysis of 18 RCTs (Tzang) - eClinicalMedicine 2025
- Weight Regain After Stopping Weight-Management Medication (West) - BMJ 2026
- Epic Research - 2 Years After Stopping
- Phentermine After Stopping a GLP-1 - Epic Research 2024
- Phentermine Prescribing Information (Contraindications) - DailyMed
Weight loss compared with surgery
- Bariatric Surgery vs GLP-1 RAs, Network Meta-Analysis of 30 RCTs (Sabatella) - Obesity 2026
- Bariatric Surgery vs GLP-1 RAs, Weight Loss and Costs (Barrett) - JAMA Surgery 2025
Benefits beyond weight loss (early evidence)
- Semaglutide and Proteomic Organ-Specific Biological Age (Dermit) - Research Square preprint 2026
- Ixekizumab With or Without Tirzepatide in Psoriasis (Lebwohl) - JAMA Dermatology 2026
- Ixekizumab With Tirzepatide in Psoriatic Arthritis (Merola) - Arthritis & Rheumatology 2026
- Semaglutide Dose and Neuropsychiatric Events Independent of Weight Loss (Murugadoss) - npj Metabolic Health and Disease 2026
- Semaglutide and Asthma Attacks (Bloom) - ERS Congress 2026
Heart
- SELECT Trial - NEJM 2023
- SELECT Weight-Independence Analysis - Lancet 2025
- SELECT Early Clinical Benefit Analysis - Arch Cardiovasc Dis 2026
- STEP-HFpEF Pooled Analysis - Lancet 2024
Kidney
- FLOW Trial - NEJM 2024
- FLOW by Baseline BMI and Weight Loss (Mann, ADA 2025 abstract 1971-LB), reported by Healio
- REMODEL: Semaglutide Kidney Mechanisms, Biopsy and MRI (Tuttle) - Nature Medicine 2026
- FDA CKD Indication - January 2025
Liver (MASH)
- ESSENCE Trial - NEJM 2025
- SYNERGY-NASH - NEJM 2024
- FDA MASH Approval - August 2025
- Weight-Loss Mediation and Proteomics in MASH (Jara) - Nature Medicine 2025
- Weight-Dependent and -Independent Effects of Semaglutide in ESSENCE (Newsome, AASLD 2025)
Joints
- STEP 9 Trial - NEJM 2024
- Gut-Joint Axis - Science 2025
- Semaglutide and Osteoarthritis, Weight-Loss-Independent Mechanism (Qin) - Cell Metabolism 2026
- TRIUMPH-4 and TRIUMPH-1-OA: Retatrutide in Knee Osteoarthritis (Schnitzer) - NEJM 2026
- Systematic Review: GLP-1 RAs in OA - Frontiers 2025
- STOP-KNEE OA Trial (Tirzepatide) - ClinicalTrials.gov
Sleep apnea
Brain and mood
- EVOKE/EVOKE+ Trials - ALZFORUM 2025
- Obesity Pharmacotherapies and Cognition (Börchers, Zetterberg, Clemmensen) - Science 2026
- Migraine Pilot Study - Headache 2025
- GLP-1 RAs and Mental Health, Meta-Analysis of 80 RCTs (Pierret) - JAMA Psychiatry 2025
- GLP-1 RAs and Worsening Mental Illness in Depression and Anxiety, Swedish Cohort (Taipale) - Lancet Psychiatry 2026
- FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Labels - January 2026
Cravings and addiction
- Exenatide AUD RCT (Klausen) - JCI Insight 2022
- Semaglutide AUD RCT - JAMA Psychiatry 2025
- SEMALCO: Semaglutide in Alcohol Use Disorder With Obesity (Klausen) - Lancet 2026
- Semaglutide in Adults Who Smoke Daily (Hendershot) - JAMA Netw Open 2026
- GLP-1 Receptor Agonists in Addiction Therapy (Volkow, Wargo) - Science 2026
- GLP-1 RAs for AUD Review - JCI 2025
Cancer
- GLP-1 and Cancer Risk - JAMA Oncology 2025
- GLP-1 RAs and 13 Obesity-Associated Cancers vs Insulin or Metformin (Wang) - JAMA Netw Open 2024
- Cancer Risk in 48 Placebo-Controlled Trials (Ko) - Ann Intern Med 2026
- GLP-1 Therapies and Cancer Risk: Interpreting the Evidence (Hicks, Pottegård) - Science 2026
Safety
- Thyroid Cancer Risk (Morales) - Diabetes Care 2025
- GLP-1 RAs and Acute Pancreatitis, Living Meta-Analysis of 31 RCTs (Bakker) - medRxiv 2026 preprint
- Pancreatitis and Pancreatic Cancer in 62 RCTs (Wen) - Endocrinol Diabetes Metab 2025
- MHRA Drug Safety Update: Strengthened Pancreatitis Warnings - January 2026
- Tirzepatide Dose-Response and Acute Pancreatitis, Meta-Analysis of RCTs - Pancreatology 2026
- GLP-1 RAs and Gallbladder and Biliary Disease, Meta-Analysis of 76 RCTs (He) - JAMA Intern Med 2022
- GI Side Effects by GLP-1 Medication in Patients With Diabetes - Epic Research 2024
- NAION in 112 Placebo-Controlled Liraglutide and Semaglutide Trials (Vilsbøll) - Br J Ophthalmol 2026